News | May 12, 2021
Dr. Reddy's launches Ertapenem in US
The INVANZ brand and generic market had U.S. sales of approximately US $205 million MAT for the most recent twelve months ending March 2021 according to IQVIA Health
The INVANZ brand and generic market had U.S. sales of approximately US $205 million MAT for the most recent twelve months ending March 2021 according to IQVIA Health
The production capacity is now ramped up to 90 lakh vials per month whereas earlier it was 40 lakh vials/month
This achievement enables the company to strengthen its presence in the high growth market of South Asian countries
The centralized marketing authorization granted by the EC is valid in all EU Member
Subscribe To Our Newsletter & Stay Updated
